E‐cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models

E‐cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models

Cell–cell and cell–matrix adhesion proteins that have been implicated in colorectal epithelial integrity and epithelial‐to‐mesenchymal transition could be robust prognostic and potential predictive biomarkers for standard and novel therapies. We analyzed in situ protein expression of E‐cadherin (ECA...

Full description

Bibliographic Details
Main Authors:	Jarle Bruun, Peter W. Eide, Christian Holst Bergsland, Oscar Bruck, Aud Svindland, Mariliina Arjama, Katja Välimäki, Merete Bjørnslett, Marianne G. Guren, Olli Kallioniemi, Arild Nesbakken, Ragnhild A. Lothe, Teijo Pellinen
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	Molecular Oncology
Subjects:	colorectal cancer drug screening E‐cadherin multiplex immunohistochemistry pharmacoproteomics prognostic biomarker
Online Access:	https://doi.org/10.1002/1878-0261.13159

Similar Items

Discovery of the Consistently Well-Performed Analysis Chain for SWATH-MS Based Pharmacoproteomic Quantification
by: Jianbo Fu, et al.
Published: (2018-06-01)

Prognostic significance of β-catenin, E-cadherin and SOX9 in colorectal cancer: results from a large population-representative series
by: Jarle eBruun, et al.
Published: (2014-05-01)

Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer
by: Jørgen Smeby, et al.
Published: (2019-06-01)

Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer
by: Bergsland, CH, et al.
Published: (2020)

Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases
by: Kushtrim Kryeziu, et al.
Published: (2021-09-01)

MiR-9, -31, and -182 Deregulation Promote Proliferation and Tumor Cell Survival in Colon Cancer
by: Lina Cekaite, et al.
Published: (2012-09-01)

Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer
by: Hege Marie Vedeld, et al.
Published: (2018-05-01)

Genomic and prognostic heterogeneity among RAS/BRAFV600E/TP53 co‐mutated resectable colorectal liver metastases
by: Kaja C. G. Berg, et al.
Published: (2021-04-01)

Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors
by: Matthias Kolberg, et al.
Published: (2017-09-01)

Protocol for 3D drug sensitivity and resistance testing of patient-derived cancer cells in 384-well plates
by: Michaela Feodoroff, et al.
Published: (2023-03-01)

The expressed mutational landscape of microsatellite stable colorectal cancers
by: Anita Sveen, et al.
Published: (2021-09-01)

STRN-ALK rearranged pediatric malignant peritoneal mesothelioma – Functional testing of 527 cancer drugs in patient-derived cancer cells
by: Astrid Murumägi, et al.
Published: (2021-04-01)

Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies
by: Kaja C. G. Berg, et al.
Published: (2017-07-01)

De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity
by: Seyed H. Moosavi, et al.
Published: (2021-09-01)

Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors
by: Dafne Jacome Sanz, et al.
Published: (2021-07-01)

Phospholipase C isozymes are deregulated in colorectal cancer--insights gained from gene set enrichment analysis of the transcriptome.
by: Stine A Danielsen, et al.
Published: (2011-01-01)

Dual role of topoisomerase II in centromere resolution and aurora B activity.
by: Paula A Coelho, et al.
Published: (2008-08-01)

C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease.
by: Johannes Landskron, et al.
Published: (2017-01-01)

High tumor cell platelet‐derived growth factor receptor beta expression is associated with shorter survival in malignant pleural epithelioid mesothelioma
by: Hely Ollila, et al.
Published: (2021-09-01)

Regulation of PBX3 expression by androgen and Let-7d in prostate cancer
by: Berge Viktor, et al.
Published: (2011-05-01)

Prognostic Impact of Tumor-Associated Macrophages on Survival Is Checkpoint Dependent in Classical Hodgkin Lymphoma
by: Kristiina Karihtala, et al.
Published: (2020-04-01)

Prison education in Norway – The importance for work and life after release
by: Christin Tønseth, et al.
Published: (2019-01-01)

Evodiamine Stabilizes Topoisomerase I-DNA Cleavable Complex to Inhibit Topoisomerase I Activity
by: Jau-Lang Hwang, et al.
Published: (2009-03-01)

Regulation of the Aurora-A gene following topoisomerase I inhibition: implication of the Myc transcription Factor
by: Valo Isabelle, et al.
Published: (2010-08-01)

Mechanism of Type IA Topoisomerases
by: Tumpa Dasgupta, et al.
Published: (2020-10-01)

DNA-Topology Simplification by Topoisomerases
by: Andreas Hanke, et al.
Published: (2021-06-01)

Multiomics characterization implicates PTK7 in ovarian cancer EMT and cell plasticity and offers strategies for therapeutic intervention
by: Juuli Raivola, et al.
Published: (2022-08-01)

Developments in Non-Intercalating Bacterial Topoisomerase Inhibitors: Allosteric and ATPase Inhibitors of DNA Gyrase and Topoisomerase IV
by: Scott Grossman, et al.
Published: (2023-02-01)

Phosphorylation of the human topoisomerase II protein
by: Fry, A, et al.
Published: (1992)

Inhibition of Topoisomerases by Metal Thiosemicarbazone Complexes
by: Xiaohua Jiang, et al.
Published: (2023-07-01)

Chromatinization modulates topoisomerase II processivity
by: Jaeyoon Lee, et al.
Published: (2023-10-01)

Antibody-supervised deep learning for quantification of tumor-infiltrating immune cells in hematoxylin and eosin stained breast cancer samples
by: Riku Turkki, et al.
Published: (2016-01-01)

Introducing arguments
by: Pylkkänen, Mariliina, 1973-
Published: (2009)

Inhibitory effects of lapachol on rat C6 glioma in vitro and in vivo by targeting DNA topoisomerase I and topoisomerase II
by: Huanli Xu, et al.
Published: (2016-11-01)

Cell of Origin Links Histotype Spectrum to Immune Microenvironment Diversity in Non-small-Cell Lung Cancer Driven by Mutant Kras and Loss of Lkb1
by: Ashwini S. Nagaraj, et al.
Published: (2017-01-01)

The role of Topoisomerase II in replication in mammalian cells
by: Muftic, D
Published: (2011)

Topoisomerase I in Human Disease Pathogenesis and Treatments
by: Min Li, et al.
Published: (2016-06-01)

Targeting DNA Topoisomerase II in Antifungal Chemotherapy
by: Kavya Kondaka, et al.
Published: (2022-11-01)

The Roles of DNA Topoisomerase IIβ in Transcription
by: Ram Madabhushi
Published: (2018-06-01)

Mechanisms regulating resistance to inhibitors of topoisomerase II
by: Ram N. Ganapathi, et al.
Published: (2013-08-01)